Oncolytic effect of Newcastle disease virus F48E9 strain on CT26 murine colon cancer
ZHONG Jian-ping1, LI Rui2, WANG Guo-song1, HONG Jun-ping1, FU Rao1, CHEN Yi-xin1, 2
1. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University, Xiamen 361102, China; 2. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China
Abstract：To evaluate the potential of Newcastle disease virulent strain F48E9 for oncolytic treatment and make a foundation of genetic modification for Newcastle disease virus F48E9 strain, the inhibitory effect of F48E9 strain on CT26 colon cancer cells was tested by CCk-8 kit in vitro and oncolytic effect of F48E9 strain on CT26 tumor-bearing mice in vivo was evaluated by intratumoral injection of F48E9 virus, the side effects of F48E9 strain on 6-week BALB/c mice was also evaluated by Intravenous injection of 2×107 pfu virus. The results showed that F48E9 at a MOI of 0.1 showed an obvious inhibition on the growth of CT26 cells. With the increase of MOI, its inhibitory effect on cell growth was significantly enhanced; the growth of CT26 murine tumor subcutaneously transplanted in BALB/c mice was significantly inhibited by 0.1 mL F48E9 strain at 2×107 pfu/mL. The average survival time of the virus-treated group was 38.4 d, and PBS-treated group was 15.2 d. Immunohistochemical experiment showed that F48E9 significantly inhibited the proliferation of CT26 cells of transplanted tumor in mice; safety evaluation of F48E9 strain by tail vein injection in normal BALB/c mice showed that the strain had no obvious side effects. The results showed that Newcastle disease virus F48E9 strain had a good therapeutic effect on CT26 colorectal cancer in vitro and in vivo and was safety on BALB/c mice. Newcastle disease virulent strain F48E9 has a good oncolytic potential for CT26 mouse colorectal cancer, and can be used as a candidate virus strain to establish a safer and more effective oncolytic virus strain through subsequent reverse genetic modification, for tumor research and treatment.
[1] 张忠涛, 蔡军. 结肠癌多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志, 2017, 1(37):44-45. DOI:10.19538/j.cjps.issn1005-2208.2017.01.15 [2] 吴琳. 结肠癌根治术后肿瘤转移复发的特点和影响预后的因素[J]. 中外医学研究, 2015, 14:127-129. DOI:10.14033/j.cnki.cfmr.2015.14.065 [3] Couzin FJ.Cancer immunotherapy[J]. Science, 2013, 342(6165):1432-1433. DOI:10.1126/Science.342.6165.1432 [4] Russell SJ, Peng KW, Bell JC.Oncolytic virotherapy[J]. Nat Biotechnol, 2012, 30(7):658-670. DOI:10.1038/nbt.2287 [5] Fountzilas C, Patel S, Mahalingam D, et al.Review:oncolytic virotherapy, updates and future directions[J]. Oncotarget, 2017, 8(60):102617-102639. DOI:10.18632/oncotarget.18309 [6] Freeman AI, Zakay RZ, Gomori JM, et al.Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme[J]. Mol Ther, 2006, 13(1):221-228. DOI:10.1016/j.Ymthe.2005.08.016 [7] Zemp FJ, Corredor JC, Lun X, et al.Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil[J]. Cytokine Growth Factor Rev, 2010, 21(2) : 103-117. DOI:10.1016/j.Cytogfr.2010.04.001 [8] Coffin R.Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immuno-therapy approved for the treatment of cancer[J]. Immunotherapy, 2016, 8(2): 103-106. DOI: 10.2217/imt.15.116 [9] Mustaffa BA, Ibrahim AL, Khim TS.A case of human infection with newcastle disease virus[J]. Southeast Asian J Trop Med Public Health, 1976, 7(4): 622-624. [10] Buijs PR, Van AG, Van NS, et al.Intravenously injected newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy[J]. Cancer Gene Ther, 2014, 21(11): 463-471. DOI: 10.1038/cgt.2014.51 [11] Pecora AL, Rizvi N, Cohen GI, et al.Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers[J]. J Clin Oncol, 2002, 20(9): 2251-2266. DOI: 10.1200/JCO.2002.08.042 [12] Laurie SA, Bell JC, Atkins HL, et al.A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization[J]. Clin Cancer Res, 2006, 12(8):2555-2562. DOI: 10.1158/1078-0432.CCR-05-2038 [13] Sinkovics JG, Horvath JC.Newcastle disease virus :brief history of its oncolytic strains[J]. J Clin Virol, 2000, 16(1):1-15. DOI: 10.1016/S1386-6532(99)00072-4 [14] 胡立华, 陈鹏, 张沛怡, 等. 新城疫病毒对人类大肠癌细胞的杀伤作用研究[J]. 牡丹江医学院学报, 2010, 31(5):11-13. DOI: 10.3969/j.issn.1001-7550.2010.05.005 [15] 梅双双, 杨润德. 鸡新城疫病毒强毒株的分离及生物学特性鉴定[J]. 中国预防兽医学报, 2002, 24(5):368-371. DOI: 10.3969/j.issn.1008-0589.2002.05.013 [16] 王明睿, 钟建平, 李睿, 等. 新城疫病毒核蛋白单克隆抗体的制备及双抗体夹心ELISA的初步建立[J].中国人兽共患病学报, 2017, 33(6):481-485. DOI: 10.3969/j.issn.1002-2694.2017.06.002 [17] Vigil A, Park MS, Martinez O, et al.Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus[J]. Cancer Res, 2007, 67(17):8285-8292. DOI: 10.1158/0008-5472.CAN-07-1025 [18] Kanthiya K, Khunnarong J, Tangjitgamol S, et al.Expression of the p16 and Ki67 in cervical squamous intraepithelial lesions and cancer[J]. Asian Pac J Cancer Prev, 2016, 17(7):3201-3206. DOI: 10.14456/apjcp.2016.76 [19] Zamarin D, Holmgaard RB, Subudhi SK, et al.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy[J]. Sci Transl Med, 2014, 6(226):226-232. DOI: 10.1126/scitranslmed.3008095 [20] Patricia K, Laetitia F, Christine T, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition[J]. Oncoimmunology, 2016, 5(10): e1220467.1-e1220467.14. DOI: 10.1080/2162402X.2016.1220467 [21] Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, et al.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model[J]. Gene Ther, 2014, 22(1):65-75. DOI: 10.1038/gt.2014.83 [22] Scholzen T, Gerdes J.The ki-67 protein: from the known and the unknown[J]. J Cell Physiol, 2000, 182(3): 311-322. DOI: 10.1002/(SICI)1097-4652(200003) [23] Vigil A, Martinez O, Chua MA, et al.Recombinant newcastle disease virus as a vaccine vector for cancer therapy[J]. Mol Ther, 2008, 16(11): 1883-1890. DOI: 10.1038/mt.2008.181 [24] Hong S, Wang K, Xie R, et al.NDV-D90 suppresses growth of gastric cancer and cancer related vascularization[J]. Oncotarget, 2017, 8(21):34516-34524. DOI: 10.18632/oncotarget. 16563
2019, Vol. 35 
